A Study of Definitive Therapy to Treat Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
To assess the safety of treating men with oligometastatic prostate cancer with the following
therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant
androgen deprivation and up to 6 cycles of chemotherapy, (2nd) definitive local tumor control
with prostatectomy +/- adjuvant radiation therapy, and (3rd) consolidative stereotactic
radiation to oligometastatic lesions. The men will receive a total of 1 year of androgen
deprivation. Androgen blockade will be the same throughout the course of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins